Call Us:  +1.302.777.7774

CECON logo

Log in

Login to your account

Username *
Password *
Remember Me
Show More
Add this resume to contact form Yes No
Back to Search Result GO

Synthetic and Medicinal Chemistry Consultant Specializing in the Integration of All Aspects of Drug Discovery; Chemistry, Biology, Patent Protection, Pre-Clinical Development and IND

Technical Consultant #1778


  • Synthetic and medicinal chemistry.
  • The integration of all aspects of drug discovery, from early-stage research in chemistry and biology, through patent protection, pre-clinical development, CMC, IND-filing and support of Phase I and II clinical trials.
  • Indication areas of experience: Inflammation, cancer, neurological and neurodegenerative diseases, age-related macular degeneration, and diabetic retinopathy.
  • 18 years of fast-paced research and management experience involving pivotal invention and/or development roles in 5 compounds through Phase I and/or II clinical trials.
  • Establishment and management of successful research programs from leads generated by:
  • High throughput screening of synthetic compounds and natural products, peptide mimetics of protein-protein interactions, native ligands, and molecular modeling (de novo and rational drug design).
  • Management of in vitro and in vivo pharmacology research and development teams.
  • Development of intellectual property strategies.
  • Establishment of commercially viable process chemistry routes to APIs.
  • Management of CMC activities for API and drug product manufacture; stability testing from candidate selection through IND filing to preparation for Phase 3 clinical trials.
  • Management of ADME programs in support of Phase 2 trials including identification, structural determination, and bioanalytical method development for all human-relevant metabolites.
  • Management of toxicology programs in support of Phase1 and 2 clinical trials including 3, 6 and 9 month toxicology studies in several species; reproductive and developmental toxicity studies and translational toxicity studies.

Medical Experience:

  • Inflammation
  • Congestive Heart Failure
  • Psoriasis
  • Parkinson's Disease
  • Schizophrenia
  • Dry-Eye

  • Cancer
  • Diabetes
  • Hypertension
  • Cocaine Abuse
  • Neuropathic Pain
  • Glaucoma

  • Alzheimer Disease
  • Rheumatoid Arthritis
  • Age-Related Macular
  • Degeneration
  • Diabetic Retinopathy

Drug Targets:

  • Kinases (P38, MAPKAP2, MK-2)
  • Growth Factors (FGF, VEGF)
  • Integrin VLA-4/%u0105 4%u03B2 1
  • Endothelin A
  • E-Selectin

  • HDAC
  • PTP-1B
  • GABA
  • %u03B2-Secretase
  • Dopamine D2

  • Retinoid Isomerization
  • RPE65
  • Serotonin
  • NMDA


Undisclosed Company, Senior Director of Chemistry and Biology, 2005 - 2010

  • Principle inventor of Phase II trials for AMD.
  • Delivery of clinical candidate in less than 9 months.
  • Discovery of 6 novel, related chemical classes.
  • Authorship of 6 patent applications.
  • Leadership of the working groups with Otsuka in areas of research, CMC, toxicology, and non-clinical pharmacology.
  • Creation of overall research plan including initial SAR, back-up program, IP, MOA studies, and the generation of new animal models for ocular disease.
  • Chemistry team leader (5 internal, 6 external chemists).
  • Biology team leader (9 biologists including the vivarium).
  • Initiated, managed and completed studies including: 3, 6, and 9-month toxicology, pilot development and pilot fertility.
  • Managed the metabolite identification program - Identified major human metabolites.
  • Managed the CRO responsible for development and validation of bioanalytical methods for parent and metabolites.
  • Designed and implemented translational toxicology studies.
  • Managed CMC including API and drug product manufacture, and submission of CMC Section 7.
  • Established and implemented patent protection strategies.
  • Managed chemistry outsourcing to India.

AMRI, Bothell, WA; Chicago, IL; Albany, NY, Executive Director, Lead Discovery, 1999 - 2005

  • Head of Operations, Bothell Research Center, Bothell, WA, 2003 - 2005
  • Head of Operations, The Biosciences Group, Chicago, IL, 2003 - 2005
  • Creator, The Oncology Group, Cross-Divisional, 2002 - 2005
  • Mandate as Head of Operations required the evaluation of ongoing research programs, teams, and scientific approaches, and to implement changes to maximize potential.
  • Responsibilities spanned all departments including science, finance, facilities, and business development.
  • Accomplished in less than two years: organizational restructuring to improve efficiency and product marketability, creation of structural analysis and microbiology teams, creation of a new high throughput screening group, institution of new protocols for the establishment of quality natural product libraries, design and management of a new building facility, creation of a new billing paradigm (the flexi-FTE), the co-invention of a novel approach for the discovery of new antibiotics from natural products.

Texas Biotechnology Corporation, Houston, TX, Assistant Director, 1992 - 1999

  • Project Team Leader: VLA-4/VCAM Integrin.
  • Project Team Leader: FGF and VEGF Growth Factor programs.
  • Responsible for design of entry compound into a new series (peptide mimetic); lead optimization.
  • Used De Novo design to discover a new class of inhibitors.
  • Principle Inventor on 4 issued U.S. patents.

Honors & Publications

Academic and Professional Affiliations

  • Member, American Chemical Society
  • Member, Royal Society of Chemistry: MRSC, CCHEM

Publications and Patents

  • 19 issued U.S. patents and 12 patent families in prosecution.
  • 34 publications (scientific, peer reviewed journals) and presentations.
  • 6 invited speaking engagements.


  • Ph.D. Synthetic Chemistry, University of Sheffield, England
  • M.Phil. Synthetic Chemistry, University of Sheffield, England
  • B.Sc. Chemistry, (with Honors), University of Sheffield, England
Back to Search Result GO